{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Sounds of Science","title":"Off-Target, On-Point: How Retrogenix® Reduces Risk and Animal Use","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/bd9cd911\"></iframe>","width":"100%","height":180,"duration":1685,"description":"In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA’s ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O’Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.Show Notes Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening Paving the Way for Enhanced Drug Development A Status Report on Cell-Based Protein Arrays Retrogenix® Human Protein Library Retrogenix®: The Screen Door of Drug Development Retrogenix® CAR Specificity Testing Charles River Launched New Retrogenix Non-Human Protein Library ","thumbnail_url":"https://img.transistorcdn.com/ZE2zIMlSzoDJ-xSt26RohDaQEx1CXFTXmgj7dMpX-dk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9hNjhm/NWQ0NDVmNDY1Njcw/NGJmMzBkMTg3OWQ3/MTdmYy5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}